普洛药业(000739) - 2024 Q1 - 季度财报

Financial Performance - The company reported sales revenue of ¥2,298,162,652.02, an increase of 15.1% compared to ¥1,996,810,525.10 in the previous period[4] - The company's operating revenue for Q1 2024 was CNY 3,198,046,619.86, representing a 3.65% increase compared to the same period last year[31] - Total operating revenue for the first quarter reached ¥3,198,046,619.86, an increase of 3.65% compared to ¥3,085,538,744.52 in the previous year[50] - The net profit attributable to shareholders was CNY 243,716,289.99, reflecting a 1.84% growth year-over-year[31] - Net profit attributable to the parent company was not explicitly stated but can be inferred from the financial data provided[41] Cash Flow - Total cash flow from operating activities for the current period was ¥280,125,473.87, an increase of 25.5% compared to ¥222,944,074.02 in the previous period[4] - The net cash flow from operating activities increased by 25.65% to CNY 280,125,473.87 compared to the previous year[31] - The company reported a net cash inflow from financing activities of ¥37,520,045.40, down from ¥102,872,647.96 in the previous year[53] - The net cash flow from financing activities decreased by 63.53% to CNY 37,520,045.40, attributed to a reduction in net borrowings[17] Assets and Liabilities - The total current assets at the end of the reporting period amounted to ¥9,054,659,617.92, up from ¥8,368,160,381.14 at the beginning of the period, reflecting a growth of 8.2%[3] - Total assets at the end of the reporting period reached CNY 13,476,350,661.11, a 5.55% increase from the end of the previous year[31] - Total assets increased to ¥13,476,350,661.11 from ¥12,767,664,072.34, representing a growth of approximately 5.56%[40] - The total liabilities at the end of the reporting period were ¥3,500,000,000.00, reflecting a stable financial position[3] - Total liabilities rose to ¥7,001,476,313.54, compared to ¥6,537,246,876.10, indicating an increase of about 7.09%[40] Equity - The company's equity attributable to shareholders rose to CNY 6,467,188,315.67, marking a 3.93% increase year-over-year[31] - The total equity attributable to shareholders increased to ¥6,467,188,315.67 from ¥6,222,728,875.43, reflecting a growth of approximately 3.93%[40] Inventory and Receivables - Accounts receivable rose to ¥2,034,676,951.20, up 20% from ¥1,695,032,971.13 in the previous period[3] - Inventory decreased to ¥1,871,338,432.27, down 10.2% from ¥2,083,301,418.08, indicating improved inventory management[3] Expenses - Total operating costs amounted to ¥2,862,663,780.78, up from ¥2,727,579,280.84, reflecting a year-over-year increase of 4.94%[50] - Research and development expenses decreased to ¥152,938,500.76 from ¥202,240,389.62, a reduction of approximately 24.38%[50] - Financial expenses showed a significant decrease of 120.80%, resulting in a gain of CNY -3,621,791.70 due to exchange rate gains[17] - Other income surged by 1466.73% to CNY 23,121,109.72, primarily due to an increase in policy-related income[17] Future Plans - The company plans to expand its market presence and invest in new product development to drive future growth[5] - The company is exploring potential mergers and acquisitions to enhance its competitive edge in the market[5]